In addition, a study observed that no SCLC transformation occurred in EGFR-mutant lung cancers without baseline TP53 and RB1 alterations, as well as that patients with EGFR/RB1/TP53-mutant NSCLC had a higher SCLC transformation rate than those with EGFR/TP53-mutant RB1-wildtype and EGFR-mutant RB1/TP53-wildtype NSCLC, indicating that TP53 and RB1 alterations may enhance SCLC transformation [18]. Here, TP53 is linked to non-small cell lung carcinoma.